AZ Latina ☮️🌊🟦

How about going on the offense against #ALS? @SecKennedy promised he'd end the war on stem cells. You can make that a reality by approving #NurOwn, the only disease modifyng treatment that is extending survival in sporadic ALS. Read the 309 pg citizens petition at Nurownworks.com. You promised to marry "gold standard science and common sense." People regaining function in a 100% fatal disease doesn't happy by pure chance. Ask Mayo's Dr Windebank or Harvard's LJ Wei. Dr Prasad promised to approve drugs for rare diseases at the "1st signs of promise." NurOwn worked in 2015 in P2, 2017-20 in P3, in 2021-2022 in EAP, and in 2019-2020 in Right to Try in 2019-20.

The most important Oscar speech tonight wasn’t about film. The director of “Mr. Nobody Against Putin” just said this from the stage: “You lose your country through countless small acts of complicity. When we act complicit when a government murders people on the streets. When oligarchs take over the media and control how we produce and consume it. We all face a moral choice. But even a nobody is more powerful than you think.” He was talking about Russia. The audience knew he was talking about America too. Elon Musk owns the platform you’re reading this on. David Ellison is buying CNN — Pete Hegseth said it will be “far better” when he does. The DOGE deposition videos were removed from YouTube. The Epstein files are sealed. The Pentagon won’t release a casualty count. Countless small acts of complicity. That’s how you lose it. A nobody is more powerful than you think. Never stop connecting the dots.

❤️"@RWitherspoon: Love spending time with this bright light, #NanciRyder❤️#ALS #FindACure instagram.com/p/BJ1ZXvag1Sl/… ZAnKJNaU4b"

Pleased to see @BarrowNeuro #neuromuscular specialist Dr. Timothy Fullam share his knowledge about #ALS on @FOX10Phoenix. He discussed ALS symptoms, the importance of prompt diagnosis, & the current state of ALS research. Watch the segment at bar.rw/fullamfox10.

In the Absence of Objective Measures for ALS, Caregivers are the Only Witnesses. We Shouldn’t Have To Be. medcitynews.com/2026/03/in-the…

Today we announced that the U.S. FDA has resumed review of our BLA for Deramiocel for the treatment of Duchenne muscular dystrophy and set a PDUFA target action date of August 22, 2026. Click here to read the announcement: bit.ly/4bz2qk2 #DMD #Deramiocel $CAPR

Honored to host FDA‘s own Jim Traficant for a discussion on rare diseases. His personal story is captivating and inspiring — we’re grateful to have him.

Treating patients with rare diseases has an impact on your soul. That's why we're moving fast.

Late Dr. Eldad Melamed—visionary founder of NurOwn stem cell therapy, Tel Aviv Univ prof, ex-president of Israel Neurological Assoc, @MichaelJFoxOrg Scientific Advisor, with 450+ papers & 36K+ citations—discusses his revolutionary neurotrophic factor "nano pumps" for ALS & Parkinson's. @SecKennedy @RobertKennedyJr @FDACBER @DrMakaryFDA @VPrasadMDMPH @MartyMakary

FDA Commissioner Dr. Marty Makary revealed a major shift at the agency that’s still making waves: “I personally meet one-on-one with reviewers and ask: ‘Are you seeing anything that gives you chills up your spine because it could be such a game-changer?’” He described the FDA’s new proactive approach: - No more passive waiting for applications. - When early data looks “too good to be true,” they call companies directly: “Forget the paperwork — send more data now.” - Fast-track vouchers for decisions in weeks instead of years. - Recent example: gene therapy restored normal hearing in 3 of 12 deaf children (improved in 7) with perfect safety — FDA contacted the company days after NEJM publication. Makary emphasized the FDA is aggressively tracking promising treatments for blindness, deafness, pediatric/rare diseases, cancers — and a “potentially promising” therapy for type 1 diabetes that has reviewers excited. This is the FDA acting like it’s on the front lines of curing disease, not just regulating it. Months later — are you hopeful this new mindset finally delivers real cures, or waiting to see hard results?

Happy to announce today regulatory flexibilities for cell and gene therapies. Patients and those working on cures deserve common sense approaches.

🔥@SenRonJohnson called out the FDA for what it is—an agency that needlessly says "no" while patients and families suffer. "It enraged me that these families, these patients, are being denied effective treatments because of regulatory roadblocks."

.@SenRonJohnson: This isn't just regulatory delay. It's cruelty Navy pilot/ALS hero @BellinaMatthew—namesake of your #RightToTry law—fought for hope. Now, #ALS patients are dying denied NurOwn, despite proven real-world survival gains Our NUROWN Citizens Petition is 2 MONTHS past the FDA's deadline. @VPrasadMDMPH is silent. @jim_traficant

a 'senior fda official' (many presume is prasad) slams fda adcoms. while adcoms aren't perfect, they are the only public way for drug developers and fda to present their arguments, and hear the views of patient advocates and physicians in response. they can be refined btw to reduce conflicts etc, but the idea you shouldn't have them is very paternalistic, and says more about this senior official not valuing the views of physicians and patients. endpoints.news/fda-official-q…

@HHSGov Great news! Now please ask FDA to mandate that drug sponsors include HBCU med schools as clinical trial sites to democratize clinical trial enrollment amongst Black Americans who are drastically underrepresented in clinical trials.

HHS is committed to advancing excellence and innovation at Historically Black Colleges and Universities. HBCUs are leading the way in preparing the next generation of doctors, scholars, and scientists. This summer, HHS is opening the Roy Wilkins Fellowship in Washington, D.C., for HBCU students. Apply by March 28: Send your resume, references, and transcript to fellowship@hhs.gov. Eligibility details view here: usajobs.gov/GetJob/ViewDet…

Shohei Ohtani and Japan just MERCY RULED Chinese Taipei 13-0 😭 Ohtani had 3 Hits, 5 RBIs, and a Grand Slam 😭😭😭

#Myeloma Paper of the Day: REALiTEC: a multi-country observational study of teclistamab in relapsed/refractory myeloma outside trials finds ORR 60.2%, ≥VGPR 52.2%; DoR 20.3 mos, PFS 9.7, OS 26.3; infections in 70.8% & CRS 55.8%; IgG given in 60%: pubmed.ncbi.nlm.nih.gov/41784028/. #mmsm

FDA is moving with unprecedented agility. Today we approved a multiple myeloma drug just 55 days after the application was filed. And last week’s approval (a major leap forward) was approved in 44 days. If a trial result shows immediate promise for many Americans, why wait?

I went to the House floor today to talk about what I've seen in the Epstein files so far. I plan on returning to the DOJ very soon — this work is far from over. This government is lying to us and I'll continue to fight until we have full transparency.

@LorrisPodcast @HerALSStory @iamalsorg This should be fantastic. Leah did so much to raise awareness about #ALS impacting young women. She will be so missed but her legacy lives on.

NEW EPISODE! A tribute to Leah Stavenhagen.💜 Three young ladies from @HerALSStory join me to chat about Leah’s legacy. Listen in and share this intimate conversation. Direct Link: 🎧 podcasts.apple.com/us/podcast/the…💜 @iamalsorg #ALS #heralsstory